ARS Pharmaceuticals Inc (NASDAQ: SPRY) has a price-to-earnings ratio that is above its average at 159.13x. The stock has a 36-month beta value of 0.77. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 56.04M, and at present, short sellers hold a 34.67% of that float. On April 09, 2025, the average trading volume of SPRY was 1.65M shares.
SPRY) stock’s latest price update
ARS Pharmaceuticals Inc (NASDAQ: SPRY) has experienced a decline in its stock price by -1.01 compared to its previous closing price of 12.33. However, the company has seen a fall of -6.48% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-20 that ARS Pharmaceuticals, Inc.’s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy’s competitive edge lies in its innovative intranasal delivery, targeting a $3 billion initial addressable market in the U.S. with potential growth prospects. Despite neffy’s potential, risks include competition, pricing pressures, and single-asset dependency, leading to a “Hold” recommendation due to commercial uncertainties.
SPRY’s Market Performance
ARS Pharmaceuticals Inc (SPRY) has experienced a -6.48% fall in stock performance for the past week, with a 5.85% rise in the past month, and a 7.63% rise in the past quarter. The volatility ratio for the week is 10.73%, and the volatility levels for the past 30 days are at 8.28% for SPRY. The simple moving average for the last 20 days is -2.59% for SPRY’s stock, with a simple moving average of -2.72% for the last 200 days.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Scotiabank repeating the rating for SPRY by listing it as a “Sector Outperform.” The predicted price for SPRY in the upcoming period, according to Scotiabank is $30 based on the research report published on March 07, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $40. The rating they have provided for SPRY stocks is “Outperform” according to the report published on February 10th, 2025.
SPRY Trading at 1.65% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.06% of loss for the given period.
Volatility was left at 8.28%, however, over the last 30 days, the volatility rate increased by 10.73%, as shares sank -0.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.57% lower at present.
During the last 5 trading sessions, SPRY fell by -6.02%, which changed the moving average for the period of 200-days by +50.12% in comparison to the 20-day moving average, which settled at $12.53. In addition, ARS Pharmaceuticals Inc saw 15.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Shawver Laura, who sale 50,002 shares at the price of $12.30 back on Apr 07 ’25. After this action, Shawver Laura now owns 210,346 shares of ARS Pharmaceuticals Inc, valued at $615,075 using the latest closing price.
Shawver Laura, the Director of ARS Pharmaceuticals Inc, proposed sale 50,002 shares at $12.30 during a trade that took place back on Apr 07 ’25, which means that Shawver Laura is holding shares at $615,051 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.99 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at 0.09. The total capital return value is set at -0.01. Equity return is now at value 3.28, with 2.74 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 322.57.
Currently, EBITDA for the company is -3.08 million with net debt to EBITDA at 16.63. When we switch over and look at the enterprise to sales, we see a ratio of 12.89. The receivables turnover for the company is 10.91for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.26.
Conclusion
To sum up, ARS Pharmaceuticals Inc (SPRY) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
